10-Q: STRATA Skin Sciences Reports Deepening Losses, Negative Working Capital

STRATA Skin Sciences reported a significant increase in net losses and a shift to negative working capital for the quarter ended June 30, 2025, alongside declining revenues and an un-remediated material weakness in internal controls.

Summary

• Net loss for the three months ended June 30, 2025, was $2.489 million, a substantial increase from $0.099 million in the same period of 2024.
• Net loss for the six months ended June 30, 2025, was $4.921 million, compared to $3.467 million for the same period in 2024.
• Total revenues decreased to $7.663 million for the three months ended June 30, 2025, from $8.435 million in the prior year, and to $14.475 million for the six months, from $15.189 million.
• Working capital turned negative, standing at $(0.2) million as of June 30, 2025, down from $2.0 million at December 31, 2024.
• Cash and cash equivalents decreased to $5.966 million at June 30, 2025, from $7.261 million at December 31, 2024.
• Net cash used in operating activities significantly increased to $2.491 million for the six months ended June 30, 2025, compared to $0.213 million in the prior year.
• The company's $5.0 million Credit Facility #3 under its Senior Term Facility was no longer available due to not meeting the required $30.0 million Dermatology Recurring Procedures Revenue condition.
• A material weakness in internal control over financial reporting related to a lack of detailed management review of account reconciliations and analyses was identified and not yet remediated as of June 30, 2025.
• The New York State Court of Appeals denied the company's motion to appeal an adverse sales tax ruling, leading to the execution of a $1.3 million appellate bond during the three months ended June 30, 2025.
• The company is in dispute with Theravant Corporation regarding earnout payments related to the 2022 acquisition of TheraClear devices, with the company believing payments are not due.

Sentiment

Score: 2

Explanation: The company reported significantly increased net losses, declining revenues across both segments, and a shift to negative working capital. Cash burn from operations intensified, and a $5.0 million credit facility tranche was unavailable due to unmet revenue targets. A material weakness in internal controls remains un-remediated, and an adverse sales tax ruling resulted in a $1.3 million payment. These factors indicate severe financial and operational challenges, outweighing minor positives.

Positives

• TheraClear device placements in dermatologists' offices increased to 161 as of June 30, 2025, from 117 as of June 30, 2024.
• Net cash used in investing activities decreased significantly to $0.138 million for the six months ended June 30, 2025, from $1.070 million in the prior year, primarily due to a greater emphasis on refurbishing recalled units.
• The company was in compliance with all financial covenants within its Senior Term Facility as of June 30, 2025.

Negatives

• Net loss per share increased to $(0.60) for Q2 2025 from $(0.03) for Q2 2024, and to $(1.18) for H1 2025 from $(0.99) for H1 2024.
• Gross profit decreased to $4.306 million for Q2 2025 from $4.977 million for Q2 2024, with gross profit percentage declining to 56.2% from 59.0%.
• Dermatology Recurring Procedures revenue decreased for both the three and six months ended June 30, 2025, compared to the prior year.
• Dermatology Procedures Equipment revenue decreased for both the three and six months ended June 30, 2025, compared to the prior year, with fewer systems sold internationally and domestically.
• The company recognized no Employee Retention Credit (ERC) in 2025, compared to $0.9 million received in 2024.
• Selling and marketing expenses increased due to higher employee-related expenses, direct-to-patient advertising, and trade show costs.
• General and administrative expenses increased primarily due to higher accounting and legal expenses and certain employee-related costs.

Risks

• Potential future pandemics could negatively impact business conditions, supply chains, workforce participation, and financial markets.
• The Russia-Ukraine War continues to disrupt global supply chains for noble gases essential for lasers, impacting supply and price, with further tightening due to the CHIPS Act.
• The Middle East conflict could impact distributors' businesses, though no direct impact has been seen yet.
• U.S. trade policy actions in 2025, including increased import tariffs, may adversely affect revenues, costs, gross profit, and customer demand, and could impact consumer confidence.
• The company has historically experienced recurring losses and is dependent on raising capital from the sale of securities.
• Ongoing sales and use tax liabilities, including a remaining accrual of $0.6 million for New York and aggregate assessments of $2.4 million for California, pose a risk of future taxes, interest, and penalties.
• The dispute with Theravant Corporation over earnout payments for the TheraClear acquisition could result in future financial obligations.
• A material weakness in internal control over financial reporting could adversely affect the company's ability to record, process, summarize, and report financial information accurately.

Future Outlook

Management believes that current cash, anticipated revenues, and operating expense management will be sufficient to meet liquidity requirements for at least the next 12 months. However, market conditions, including potential future pandemics, geopolitical conflicts, and rising interest rates, could hinder the ability to access favorable financing. The company plans to increase direct-to-patient advertising for XTRAC in the United States to boost treatment usage.

Management Comments

• "Our strategy going forward is to continue to increase our direct-to-patient program for XTRAC advertising in the United States, targeting psoriasis and vitiligo patients through a variety of media and through our use of social media such as Facebook and X (formerly Twitter), and aimed at motivating them to seek out XTRAC treatments from our physician partners."
• "Management believes that the Company's cash and cash equivalents, the anticipated revenues from the sale or use of its products and operating expense management will be sufficient to satisfy the Company's working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations for at least the next 12 months following the date of the issuance of these condensed consolidated financial statements."
• "The Company has notified Theravant that it believes the earnout payments are not due and will not be due in the future. Theravant has disputed the Company's position, and the matter is under discussion among the signatories to the purchase agreement."
• "Management has concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level because of a material weakness in our internal control over financial reporting that had not yet been remediated at June 30, 2025."

Industry Context

The medical technology industry, particularly in dermatology, faces ongoing challenges from global supply chain disruptions, rising material costs, and geopolitical instability impacting critical component supplies like noble gases. The company's focus on excimer lasers for psoriasis and vitiligo, and intense pulsed light for acne, positions it in a competitive market where insurance reimbursement and patient awareness are key drivers. The decline in XTRAC system placements and overall revenue suggests a struggle to maintain market penetration or expand effectively, contrasting with the growth in TheraClear device placements, indicating a mixed performance within its product portfolio. The industry also continues to navigate the lingering effects of the COVID-19 pandemic on physician practices and elective procedures.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The New York State Court of Appeals denied the company's motion to appeal an adverse sales tax ruling, leading to the execution of a $1.3 million appellate bond during the three months ended June 30, 2025.
• The company has a remaining accrual of $0.6 million, including penalties and interest, for New York sales tax as of June 30, 2025.
• The company is in the administrative process of appeal for an additional $1.9 million of sales tax assessments in the State of New York.
• The State of California has made aggregate sales tax assessments of $2.4 million, including penalties and interest, covering June 2018 through June 2022, which the company is appealing.
• The company is in dispute with Theravant Corporation regarding earnout payments of up to $3.0 million related to the TheraClear acquisition, with the company believing the payments are not due.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises, increased net losses, negative working capital, and an un-remediated material weakness in internal controls, which could erode shareholder value.
• **Creditors:** The company's deteriorating financial performance, including increased losses and negative working capital, could raise concerns about its ability to service its debt obligations, despite current covenant compliance.
• **Customers (Physicians):** May experience continued impact from the company's reduced direct-to-patient advertising in prior periods, though the company plans to increase this going forward. The decline in XTRAC system placements suggests potential challenges in customer acquisition or retention.
• **Employees:** The company's financial struggles and operational challenges could create uncertainty regarding job security or future compensation, although employee-related expenses increased in selling, marketing, and general & administrative categories.

Next Steps

• Continue to increase direct-to-patient advertising for XTRAC in the United States to motivate psoriasis and vitiligo patients to seek treatments.
• Improve processes and controls, including senior management review, to remediate the material weakness in internal control over financial reporting.
• Continue the administrative process of appeal for the remaining $1.9 million of sales tax assessments in New York and $2.4 million in California.
• Engage in discussions with Theravant Corporation regarding the disputed earnout payments for the TheraClear acquisition.
• Evaluate the full effects of the U.S. 'One Big Beautiful Bill Act' on income taxes, effective after December 15, 2024.
• Evaluate the effect of ASU 2024-03 on income statement expense disclosures, effective after December 15, 2026.
• Evaluate the effect of ASU 2025-05 on credit loss measurement for accounts receivable and contract assets, effective after December 15, 2025.

Key Dates

Recommendation

The company's financial performance is severely deteriorating, marked by a substantial increase in net losses, declining revenues across both key segments, and a shift to negative working capital. The significant cash burn from operating activities, coupled with the unavailability of a $5.0 million credit facility tranche due to unmet revenue targets, highlights acute liquidity concerns. The un-remediated material weakness in internal controls over financial reporting indicates fundamental operational deficiencies and a lack of financial oversight. Furthermore, the adverse sales tax ruling in New York, resulting in a $1.3 million payment and ongoing disputes, adds to financial uncertainty and potential future liabilities. Geopolitical and trade risks further complicate the outlook. While management expresses confidence in liquidity for the next 12 months, the underlying financial trends and operational issues suggest a high-risk investment profile with significant downside potential, warranting a strong sell recommendation.

Keywords

Dermatology, Medical Technology, XTRAC, Pharos, Excimer Laser, Psoriasis, Vitiligo, TheraClear X, Acne Therapy, SEC Filing, 10-Q, Financial Results, Revenue, Net Loss, Working Capital, Internal Controls, Sales Tax, Liquidity, Capital Raise